Value through Innovation25 July 2014

Our five major Research Areas

Boehringer Ingelheim's successes in research & development continuously strengthen our portfolio of medications and offer patients true therapeutic benefit. The company focuses on five major research areas: CardioMetabolic diseases, Central nervous system diseases, Immunology and Inflammation, Oncology and Respiratory diseases.

Our Key Research Areas

  • CardioMetabolic Diseases Research
    Cells of the pancreas of a diabetic (Copyright: Lennart Nilsson)

    Many years of experience in this therapeutic area have allowed us to help millions of patients affected by potentially life-threatening cardiovascular and metabolic diseases. Our research and development has resulted in important achievements in recent years, especially in thromboembolic diseases and type 2 diabetes.

    Our current research efforts in the field of cardiovascular (atherosclerosis and PAOD) and chronic kidney diseases are designed to develop treatments that will influence the course of these life-threatening diseases. In metabolic diseases, we focus on new strategies for the treatment of diabetes, diabetic retinopathy, non-alcoholic Steatohepatititis (NASH), and obesity. Together with the treatment of hypertension, these therapies complement each other to reduce the risk of cardiovascular mortality and morbidity.

    Around 300 scientists work in our fully integrated drug discovery centre of excellence for CardioMetabolic research at sites in Biberach, Germany and Ridgefield, CT, USA. With extensive capabilities in both small molecules and biotherapeutics, they are working with many academic and corporate partners to discover new treatments to address continually evolving unmet medical needs.

    Research focus on: 

    • Diabetes Type 2
    • Diabetic Retinopathy
    • Non-alcoholic Steatohepatititis (NASH)
    • Obesity
    • Atherosclerosis/PAOD
    • Chronic kidney disease

    Specific opportunities for reseach partnering include:

    • Beta-cell degeneration/regeneration
    • Brown adipose tissue
    • Inflammatory processes and plaque stability/rupture in atherosclerosis/ PAOD
    • Fibrotic processes in chronic kidney diseases
    • Translational aspects especially in atherosclerosis and chronic kidney diseases (i.e. predictive animal models, imaging etc)
    • Pathogenesis of diabetic retinopathy

    If you have a research project outside these specific areas and would like to explore opportunities to partner please contact us with more information. 

    To discover our recent publications in immunology and inflammation please visit our Scientific Publication Pages.

  • Central Nervous System Diseases Research
    Synapses: Contacts between nerve cells in humans (Copyright: Lennart Nilsson)

    Progressive degeneration of the nerve cells is typical for all chronic neurological diseases. Our scientists are investigating ways of identifying and developing new treatments which can intervene in the process. The aim is to provide patients and doctors with improved treatments to address the symptoms of these diseases, and to find ways of inhibiting the basic pathological processes, which are responsible for disease progression.

    Recently, we extended our research efforts into psychiatric diseases. We recognize that the current classification of psychiatric diseases does not reflect the underlying neurobiology. Therfore, our goal is to identify and analyse multiple psychiatric diseases.

    More than 200 scientists work at our fully integrated CNS drug discovery centre in Biberach, Germany. Using their own capabilities in both small molecules and biotherapeutics, and working together with their academic and corporate partners, their focus is on disease pathophysiology and genetics to drive pathway and target selection.

    Research focus on:

    • Alzheimer’s and Parkinson’s diseases
    • Psychiatric indications – major symptoms domains i.e. cognitive impairment and negative symptoms associated with schizophrenia and underlying brain circuitry

    Specific opportunities for reasearch partnering include:

    • Selective modulation of synaptic plasticity
    • Interference in neurodegenrative pathways
    • Behavioural tests and models for defined symptom domains
    • Circuit genetics
    If you have a research project outside these specific areas and would like to explore opportunities to partne please contact us with more information.
     
     
    To discover our recent publications in immunology and inflammation please visit our Scientific Publication Pages.
  • Immunology and Inflammation Research

    Diseases, such as rheumatoid arthritis and Crohn`s disease, are chronic, lifelong disorders which are driven by aberrant immune responses and have significant impact on patient`s quality of life. Although effective therapies are available significant unmet medical need remains, as many patients are unresponsive to treatment or lose therapeutic benefit over time.

    Our fully integrated research centre of 200 scientists in Ridgefield, CT, USA has extensive capabilities in small molecule and biotherapeutic drug discovery, and partners with both academic and biotechnology partners in their efforts to discover new therapeutic options to treat these chronic progressive disorders.

    Research focus on:                

    • Rheumatoid arthritis
    • Systemic lupus erythematosus
    • Inflammatory bowel diseases such as Crohn`s disease and ulcerative colitis
    • Graft-vs.-host disease and transplantation 
    • Multiple sclerosis
    • Systemic sclerosis-scleroderma 

    Specific opportunities for reasearch partnering include:

    - Building deep expertise in core pathways and targets asociated with disease-relevant processes:

    • Adative immunity and co-stimulation (e.g. effector cells and autoantibodies)
    • Innate effector function (e.g. macropahages and dendritic cells)
    • Tissue regulation (e.g. epithelial-immune interactions)

    - Translational concepts that facilitate precision medicine

    • Deep understanding and validation of molecular targets in disease
    • Access to samples from well-annotated patients cohorts
    If you have a research project outside these specific areas and would like to explore opportunities to partner please contact us with more information.
     
     
    To discover our recent publications in immunology and inflammation please visit our Scientific Publication Pages.
  • Oncology Research

    Opportunities for effective drug discovery in oncology have never been better. Blueprints of the genetic and biochemical workings of cancer cells allow scientists in our laboratories to focus on promising targets for potential new therapeutic approaches. The impact of modern cancer genetics and immunotherapy on drug discovery is already changing the practice of medicine in oncology, with both biopharmaceuticals and small-molecules contributing to a growing repertoire of therapies.

    Our fully integrated drug discovery centre in Vienna, Austria has more than 250 scientists with extensive capabilities in both small molecule and biotherapeutic discovery.  A large number of collaborations with both academic partners and biotechnology companies are supporting our search for novel targets, biomarkers, drug candidates and treatment modalities.

    Research focus on:                        

    • Growth/survival signalling
    • Stem cell pathways
    • Epigenetic regulation of gene expression
    • Tumor angiogenesis
    • Immunotherapy
    Specific opportunities for research partnering include:

    • New insights into established and emerging cancer pathways/mechanisms
    • Potential new drug targets e.g. from cancer genomics or functional screens
    • Integrated cancer genome information to discover patient selection markers for novel precision medicines
    • Ways to engage the immune system to eliminate cancer cells

    If you have a research project outside these specific areas and would like to explore opportunities to partner please contact us with more information.

    To discover our recent publications in immunology and inflammation please visit our Scientific Publication Pages.

    News Topic

  • Respiratory Diseases Research
    Micrograph of the lung mucosa (Copyright: Lennart Nilsson)

    Boehringer Ingelheim is one of the leading pharmaceutical companies worldwide in the treatment of respiratory diseases.

    More than 200 scientists in our fully integrated drug discovery centre for respiratory research in Biberach, Germany are investigating both small molecules and biotherapeutics for the treatment of respiratory diseases. Together with their academic and biotechnology partners, their aim is to offer patients and doctors improved therapies with high efficacy, few side effects and convenient dosage forms and regimens.

    Research focus on:    

    • Inflammatory cascades in asthma and COPD (Chronic Obstructive Pulmonary Disease)
    • Airway re-modelling e.g. mucus de-regulation
    • Exacerbation prevention
    • Fibrosis
    • Acute Respiratory Distress Syndrome (ARDS)

    Specific opportunities for research partnering include:

    • Steroid (resistance) insensitivity in severe asthma and COPD
    • Models to study mechanisms to resolve inflammation in the diseased lung
    • Animal models of exacerbation and smooth muscle proliferation
    • Mimicking smoke-induced pathology in vitro
    • Knock-down technologies in rodent lung
    • Mechanisms of acute lung injury
    • Prevention of asthma by immunomodulation/desensitisation
    • Acess to human mast cells and lung tissue of asthmatics, IPF and COPD patients

    If you have a research project outside these specific areas and would like to explore opportunities to partner please contact us with more information.

    To discover our recent publications in immunology and inflammation please visit our Scientific Publication Pages.

Partner with us

Children on footbridge over stream

Within our areas of therapeutic focus we are looking to build our expertise and partner with academic institutions, non-profit research centres and biotechnology companies to embrace all stages of the research continuum:

Current translation of medical science into effective treatments is poor. We want to improve our understanding of the underlying mechanisms and causes of disease so we can contribute to biological knowledge and search for treatments that will treat disease more effectively.

With ever changing scientific horizons we know we need to work with external knowledge centres to gain access to new and evolving technologies so we can strive for excellence in both small molecule and biological treatments.  Click here to see an example of Discovering together.

We also seek partnerships, in our areas of therapeutic focus, where we can work together to discover and develop new projects. 

View details on our partnering website.

Research & Development

Research & Development

Oncology Websites

No flash player detected. For optimized usage of this website your browser should support shockwave flash. For downloading see Macromedia Flash Player